Mogamulizumab May Be Effective for Aggressive R/R Adult T-cell Leukemia/Lymphoma
Mogamulizumab induced an encouraging response rate in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
ASCO 2016
Cobimetinib Plus Atezolizumab Active in Colorectal Cancer
Cbimetinib and atezolizumab was well tolerated and demonstrated encouraging clinical activity in microsatellite stable colorectal cancer (CRC).
Nivolumab ± Ipilimumab Demonstrates Encouraging Activity, Survival in mCRC
Nivolumab with or without ipilimumab was well tolerated in most patients with high microsatellite instability metastatic colorectal cancer (mCRC).
More ‘Real-world’ Data Needed on Cost of Cancer Treatments
More transparency regarding the costs of various treatment regimens in real time is needed to “choose wisely” for patients, providers, and payers.
Drug, Genomic Innovations Have Transformed Thyroid Cancer Treatment
There were no effective therapeutic options for advanced thyroid cancer until 5 years ago.
Low Peripheral TCR Clonality Linked to Improved Survival With Atezolizumab
In patients with metastatic urothelial carcinoma treated with atezolizumab, low peripheral T-cell receptor (TCR) clonality was associated with survival.
WNT/beta-catenin Pathway Signaling Activated in Most Solid Tumors
WNT/β-catenin pathway signaling is associated with T cell exclusion and is activated in most human solid tumors, including colon, kidney, and lung tumors.
Advanced Mismatch Repair Deficiency Tumors Respond to Pembrolizumab
Patients with mismatch repair deficiency cancers may receive durable clinical benefit with pembrolizumab.
Treating Anti-PD-1-treated Patients With mNSCLC Beyond Progression Generally Not Effective
Patients with non-small cell lung cancer (NSCLC) treated with anti-programmed cell death-1 (anti-PD-1) therapy generally do not benefit from treatment.
Frontline Nivolumab Plus Ipilimumab Demonstrates Clinical Activity in Advanced NSCLC
First-line therapy with nivolumab in combination with ipilimumab demonstrated clinical activity in non-small cell lung cancer (NSCLC).
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO 2016
Loading... 
Loading...